© 2019 Bruder Consulting & Venture Group, All Rights Reserved.  New York, United States

OUR CLIENT BASE

"The Team at Bruder Consulting & Venture Group has a rich history of engagement with some of the world's most interesting, diverse and specialized organizations.  Our current cadre of clients includes medical device, biotech and cell therapy firms in the USA, Japan, Europe, Singapore and China." - Scott Bruder, MD, PhD

 

To learn more about the business of our current clients and prior experiences, click on an icon below.

Testimonials

 

"Scott and his Team have become an essential part of our strategic plan, quickly demonstrating the enormous value they provide by addressing every challenge we throw their way." - Giorgio Ninzoli, CEO, Lipogems S.p.A.

"Scott has a wonderful ability to integrate with a wide variety of partners, especially given the great distance and unique culture of our Japanese company.  His knowledge and negotiation style with the FDA has been invaluable to our success." - Ei Yamada, PhD, CEO, AnGes Inc.

"Working with Scott's team has been a force multiplier to execute our product development and regulatory priorities both smarter and faster.  I expect Scott's Group to continue to provide us with exceptional development support and regulatory guidance for years to come." - Jeff Conroy, CEO, Embody, LLC

 

"Dr. Bruder has been a trusted and invaluable colleague for two decades, so as we built a new business two years ago, he was the obvious 'Yoda' for our Clinical and Scientific Advisory Board. He brings insight, connectivity, guidance and deep commitment to our success." - Ravi Kapur, PhD, CEO, MicroMedicine

“At a challenging and pivotal time in our company, Scott was able to quickly assess our needs, effectively identify and partner with surgeon KOLs, and generate important feedback regarding our clinical trial enrollment needs.  Along with much-needed development insights to one of our research programs, he was able to add tremendous value to the Company as we were seeking to accelerate enrollment of our trial.  His extraordinary reputation in our field is well deserved.” - Adam Gridely, President and CEO, Histogenics Corporation

"Scott has been a key contributor to our most important initiatives for over two years.  Not only has he helped us navigate FDA with great credibility and insight, he has applied his expertise and can-do attitude to anything we need help with, whether reviewing animal histology, editing clinical study protocols or designing global data collection strategy." - Tanner Howe, President and CEO, AgNovos, Inc.